Multiplexed Gene Assays by Microtiter Plate Microarrays

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI056008-01
Agency Tracking Number: AI056008
Amount: $111,600.00
Phase: Phase I
Program: SBIR
Awards Year: 2003
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
893 N. WARSON RD., ST. LOUIS, MO, 63141
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (314) 812-8144
Business Contact
Phone: (314) 812-8160
Research Institution
DESCRIPTION (provided by applicant): The drug discovery industry is under increasing pressure to rapidly prioritize compound candidates based on their efficacy and specificity. Although traditional chip based gene expression microarrays can provide significant insights, sample format and throughput considerations preclude more widespread use. Microtiter plate based microarray (MPMA) systems can be directly integrated into the existing drug discovery process and would address the need for high sample throughput multiplexed gene expression assays. Apath LLC, an antiviral drug discovery company, and ProteoPlex, a microtiter plate based microarray company propose a collaboration to develop a multiplexed gene expression assay suitable for drug discovery applications such as toxicant identification. ProteoPlex has developed systems for spotting up to 144 oligonucleotide probes per microtiter well and Apath has well characterized viral replicon systems and cytotoxicity data that facilitate assay validation. We initially plan to optimize assay sensitivity and reproducibility through use of purified in vitro transcripts and modification of the probe deposition, hybridization, and cDNA target labeling conditions. We will next demonstrate that the MPMA can faithfully reproduce dose response effects by focusing on the well characterized interferon mediated inhibition of viral replicon RNAs. Finally, we will demonstrate the utility of the MPMA in identification of active and toxic compounds by performing blinded screens on panels of well-characterized compounds and comparing the results to those obtained in standard cytotoxicity assays.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government